/ THE SHORT ANSWER
- 01Use the current QMSR and February 2026 FDA guidance context.
- 02Assess functions and integrations rather than treating every feature alike.
- 03Retain assurance evidence through configuration and supplier changes.
/ dotSuper point of view
Software assurance becomes more useful when evidence follows the function that can affect product decisions, rather than the software brand.
Use the current regulatory starting point
1] Manufacturers should establish their applicable requirements from that current framework rather than assume an old software checklist remains sufficient.
FDA's February 2026 software-assurance guidance describes a risk-based approach for production and quality-management system software and supersedes its September 2025 guidance.[
2] Distinguish this nonbinding guidance from the regulation.
Our implementation advice translates that context into a function-level work plan.
Begin with the systems that influence product acceptance, process execution, traceability, or quality records.
Confirm scope with the responsible quality and regulatory team.
The article does not assume that every supplier or every software application is covered in the same way.
Describe intended use at the function level
Those functions can have different failure consequences.
Document what each important function is intended to do and what people rely on it to decide.
Include the actual configuration, interfaces, and operating context.
A vendor's standard feature may behave differently after custom rules, imported spreadsheets, or local permissions are added.
Assurance evidence should address the use the manufacturer has implemented.
Ask the process owner to describe a credible failure in ordinary language.
For example, a stale status could permit work to proceed despite an unresolved hold.
That description helps engineers choose meaningful evidence rather than test screens without considering their consequences.
Build evidence around consequential failures
The appropriate methods and rigor require the manufacturer's qualified judgment.
Avoid treating this article's table as a mandatory regulatory template.
Evaluate more than the happy path.
Include wrong permissions, missing data, duplicate messages, interrupted transfers, incorrect units, and failed synchronization where relevant.
Determine whether the function fails visibly and whether the operating process can recover without losing important records.
Retain enough evidence to explain the decision to use the function.
Screenshots may help, but they are weaker when detached from the scenario, expected result, observed result, and review.
Make the record intelligible to someone who did not run the activity.
| Area | Evidence to define |
|---|---|
| Intended use | Function, users, and business decisions |
| Risk | Credible failure and product or quality consequence |
| Configuration | Version, rules, interfaces, and permissions |
| Assurance | Relevant scenarios and observed results |
| Review | Rationale and authorized decision |
| Maintenance | Change triggers and ongoing ownership |
Worked hypothetical: a release flag crosses systems
The integration updates a lot's release status after the approved quality decision.
A network interruption could leave the receiving system with an outdated status or cause a repeated update.
The assurance plan includes an interrupted transfer, a repeated message, an unauthorized status change, and a later withdrawal of release.
The team evaluates how each condition appears in both systems and how the responsible people identify and resolve the discrepancy.
This is a proposed workflow, not a validated configuration.
The acceptance basis must come from the manufacturer's intended use and risk assessment.
A successful normal transfer alone would leave the consequential interruption and reversal cases unexplored.
Do not outsource the intended-use decision to the vendor
Ask about tested versions, configuration assumptions, known limitations, change notices, and available evidence.
Record the gaps between the supplier's environment and the actual implemented function.
Pay particular attention to automatic updates and integrations maintained by third parties.
Establish how the quality team learns that a relevant function has changed.
A release note arriving in an unmonitored administrator inbox is not a dependable change process.
For AI features, distinguish drafting a narrative from influencing a product or quality decision.
Define the permitted use, review, and source evidence.
Do not assume that adding a human approval button resolves every risk introduced by generated content.
Keep assurance connected to ongoing operation
A function may gradually acquire more authority than its original assurance record describes.
Capture that change before normal practice outruns the documented basis.
Select the next assurance activity by consequence and uncertainty.
A small release-status integration with weak evidence may deserve attention before a large low-impact reporting feature.
Document the prioritization so the team can explain why it chose that order.
The immediate deliverable is a reviewed function map and evidence plan for one consequential workflow.
Connect it to configuration, supplier changes, and operating ownership.
That approach makes software assurance part of maintaining a dependable quality system rather than a one-time binder exercise.
What this page cannot conclude
- 01This article does not determine device classification, QMSR applicability, or inspection readiness for a particular manufacturer.
- 02FDA software-assurance guidance contains recommendations; the proposed checklist is not a substitute for applicable requirements.
- 03No validation service, regulatory credential, or FDA approval is claimed for dotSuper.
- 04This article was researched and drafted with AI assistance. Sources and limitations are provided for scrutiny; it is not an independent professional review or a compliance certification.
Sources
- 01Quality Management System RegulationUS Food and Drug Administration · accessed Sep 15, 2026
- 02Computer Software Assurance for Production and Quality Management System Software, February 2026US Food and Drug Administration · accessed Sep 15, 2026
This article was researched and drafted with AI assistance. Sources and limitations are provided for scrutiny; it is not an independent professional review or a compliance certification.
Our editorial standard · Found an error? Send a correction with its source.
/ CITE OR SHARE THIS GUIDE
Make the evidence easy to verify.
When you reference this guide, link to its canonical URL. That gives readers one stable place for the evidence, limitations and future updates.
dotSuper Research Desk. (September 15, 2026). Connect QMSR Software Assurance to Actual Device Risk. dotSuper. https://dotsuper.net/feeds/applied-systems/us-medical-device-qmsr-software-assurance